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Abstract 
Microglia are instrumental for recognition and elimination of amyloid β1-42 oligomers (AβO), 
but the long-term consequences of AβO-induced inflammatory changes in the brain are unclear. 
Here, we explored microglial responses and transciptome-level inflammatory signatures in the 
rat hippocampus after chronic AβO challenge. Middle-aged Long Evans rats received 
intracerebroventricular infusion of AβO or vehicle for 4 weeks, followed by treatment with 
artificial CSF or MCC950 for the subsequent 4 weeks. AβO infusion evoked a sustained 
inflammatory response including activation of NF-κB, triggered microglia activation and 
increased the expression of pattern recognition and phagocytic receptors. Aβ1-42 plaques were 
not detectable likely due to microglial elimination of infused oligomers. In addition, we found 
upregulation of neuronal inhibitory ligands and their cognate microglial receptors, whilst 
downregulation of Esr1 and Scn1a, encoding estrogen receptor alpha and voltage-gated 
sodium-channel Na(v)1.1, respectively, was observed. These changes were associated with 
impaired hippocampus-dependent spatial memory and resembled early neurological changes 
seen in Alzheimer’s disease. To investigate the role of inflammatory actions in memory 
deterioration, we performed MCC950 infusion, which specifically blocks the NLRP3 
inflammasome. MCC950 attenuated AβO-evoked microglia reactivity, restored expression of 
neuronal inhibitory ligands, reversed downregulation of ERα and Na(v)1.1, and abolished 
memory impairments. Furthermore, MCC950 abrogated AβO-invoked reduction of serum IL-
10. These findings provide evidence that in response to AβO infusion microglia change their 
phenotype, but the resulting inflammatory changes are sustained for at least one month after the 
end of AβO challenge. Lasting NLRP3-driven inflammatory alterations and altered 
hippocampal gene expression contribute to spatial memory decline. 
 
 
Keywords  
amyloid β1-42 oligomer, hippocampus, microglia, NLRP3 inflammasome, estrogen receptors, 
spatial memory 
 
  
4 
 
Introduction 
Microglia constantly survey the brain parenchyma (Nimmerjahn, Kirchhoff, & Helmchen, 
2005) and react promptly to disturbances to maintain homeostasis (Hanisch & Kettenmann, 
2007). Microglia are equipped with receptors to monitor neurotransmission, neuronal damage, 
and to recognize any foreign or harmful substances (Lucin & Wyss-Coray, 2009). Microglial 
cells are instrumental in the recognition and elimination of amyloid beta (Aβ). Cell surface 
receptors including scavenger receptors (El Khoury et al., 1996), CD14, TLR2 and TLR4 
(Reed-Geaghan, Savage, Hise, & Landreth, 2009) bind Aβ, resulting in activation of NF-κB 
(Li, Long, He, Belshaw, & Scott, 2015). Activation of NF-κB triggers transcription of a set of 
proinflammatory genes (Muruve et al., 2008) including IL1B and NLRP3. Thereafter, encounter 
of Aβ lysosomal fragments and NLRP3 facilitates formation and activation of the NLRP3 
inflammasome complex which promotes the release of IL-1β and IL-18, modulates eicosanoid 
synthesis, autophagy, metabolism and gene transcription (Rathinam & Fitzgerald, 2016). 
Activation of the NLRP3 inflammasome has been demonstrated in Alzheimer’s disease (AD), 
and suggested that it plays a causative role in disease pathogenesis (Halle et al., 2008; Heneka 
et al., 2015). Recent preclinical studies have supported this notion. Genetic ablation of Nlrp3 
improves memory in APP/PS1 mice (Heneka et al., 2013), whilst pharmacological inhibition 
of the NLRP3 inflammasome reduces genotype-related microglia activation and enhances 
memory in transgenic mouse models (Daniels et al., 2016; Dempsey et al., 2016).  
Aβ peptides form soluble oligomers of various sizes, and aggregate into amyloid fibrils that 
gradually accumulate as insoluble senile plaques in the AD brain (Ahmed et al., 2010; Burdick 
et al., 1992; Halverson, Fraser, Kirschner, & Lansbury, 1990; Kirschner et al., 1987; Kuo et al., 
1996). The presence of activated microglia, many of which express IL-1 (Griffin et al., 1989), 
has been demonstrated at the plaques throughout the cerebral cortex (Itagaki, McGeer, 
Akiyama, Zhu, & Selkoe, 1989; McGeer, Itagaki, Tago, & McGeer, 1987). While Aβ1-42 fibrils 
are unable to evoke a strong microglial response, soluble Aβ1-42 oligomers (AβO) activate 
microglia at the low nanomolar concentrations (Maezawa, Zimin, Wulff, & Jin, 2011). Soluble 
AβO has been implicated in the pathogenesis of AD (Bilousova et al., 2016; Lesne et al., 2006; 
Muller-Schiffmann et al., 2016; Shankar et al., 2008; Wang et al., 2017). The correlation 
between the degree of dementia in AD and the level of soluble AβO (Lue et al., 1999) supports 
this notion.   
Infusion of Aβ1-42 into the cerebral ventricles of young adult rats is an established approach to 
mimic the neurological phenotype of late-onset AD (Forny-Germano et al., 2014; Garcia-Matas 
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et al., 2010; He et al., 2012; Lecanu, Greeson, & Papadopoulos, 2006). Early studies suggest 
that Aβ fibrils alone are not effective to induce memory loss, but pro-oxidant agents potentiate 
the effect of Aβ1-42, and the mixture of Aβ1-42 and pro-oxidants causes microglia activation and 
memory disturbances (Lecanu et al., 2006). Recent studies have demonstrated that AβO diffuse 
into the brain parenchyma (Forny-Germano et al., 2014) and evoke a more robust microglial 
response and memory loss than do Aβ1-42 fibrils (He et al., 2012). Aging remains the major risk 
for the development of dementia. As age-related changes of the rat hippocampal transcriptome 
already occur at 6 month of age (Kadish et al., 2009), middle-aged rats have also been used in 
Aβ infusion experiments (Frautschy et al., 2001; Frautschy, Yang, Calderon, & Cole, 1996). 
However, it is currently unclear whether AβO itself induces long-lasting inflammatory changes 
in the brain and memory deficits in an NLRP3-dependent manner. 
In this study, we examined the impact of a 4-week AβO infusion into the lateral cerebral 
ventricle of middle-aged Long Evans rats on microglia phenotype, inflammatory changes and 
transcriptomic fingerprints involved in neuron-microglia communication, estrogen signaling, 
inhibitory interneuron function and spatial memory. We also explored putative mechanisms 
that may link the microglial and inflammatory responses to AβO infusion and spatial memory 
impairments.  
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Experimental procedures 
Reagents 
Aβ1-42 peptide was purchased from Bachem (Bubendorf, Switzerland). Buthionine sulfoximine 
and iron sulfate heptahydrate were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA) and Sigma (St. Louis, MO, USA), respectively. Rabbit polyclonal antiserum to Iba1 was 
ordered from Wako Chemicals GmbH, (Neuss, Germany). Monoclonal anti-Aβ antibody was 
obtained from Abcam (Cambridge, UK). Artificial CSF and MCC950 (Coll et al., 2015) were 
purchased from Tocris (Bristol, UK) and Sigma, respectively.  
Preparation of Aβ1-42 oligomers 
Aβ1-42 peptide (Bachem, H-1368) was dissolved in 10% (w/v) NH4OH (Ryan et al., 2013). 
Aliquots were prepared, freeze dried, and stored at -20oC. Prior to use, 1 mg of Aβ1-42 was 
dissolved by adding 20 µl of 60 mM NaOH and immediately diluted with 80 µl water. Then, 
the alkaline solution was neutralized with 1.011 ml of low salt buffer (10 mM HEPES pH7, 10 
mM NaCl) to make a 0.2 mM Aβ1-42 solution. The solution was incubated for 4 hours on ice to 
promote oligomer formation (Ahmed et al., 2010). As pro-oxidant agents potentiate the effect 
of Aβ (Garcia-Matas et al., 2010; Lecanu et al., 2006), we added 2.5 ml low salt buffer 
containing 10 mg FeSO4·7H2O and 96 mg buthionine sulfoximine to the AβO solution. The 
resulting solution consisted of 61.5 µM AβO, 10 mM FeSO4 and 0.12 M buthionine 
sulfoximine. In parallel, the same solution without Aβ1-42 was prepared and used for the 
treatment of control animals. Alzet 2004 minipumps (Durect, Cupertino, CA, USA), filled with 
these solutions, were incubated at room temperature for 16 hours in saline before use. 
Experimental animals 
Young male Long Evans rats were obtained from Charles River Laboratories (Calco, Italy). 
Animals were housed in the animal care facility of Institute of Experimental Medicine for the 
subsequent months. Eight month old rats were used in the study. APPNL-F/NL-F mice were 
generated by Takaomi Saido’s laboratory (Nilsson, Saito, & Saido, 2014; Saito et al., 2014). 
For generation of the transgenic animal, the targeting vector was the mouse APP gene which 
included the Swedish and the Iberian human APP mutations (Mullan et al., 1992). The Aβ 
sequence within the mouse APP was humanized. These mice have normal levels of full length 
APP, but show increased Aβ1-42:Aβ1-40 ratio characteristic for AD pathology (Hardy, 1997). 
Animals were kept under normal conditions, with 12/12 hour light cycles, food and water was 
available ad libitum. Unlike in any other existing AD mouse models, the APPNL-F/NL-F mice 
reproduce human AD pathology with the highest fidelity. All studies were carried out with 
7 
 
permission from the Animal Welfare Committee of Institute of Experimental Medicine 
(Permission Number: A5769-01), and in accordance with the legal requirements of the 
European Community (Directive 2010/63/EU). Animal experimentation described was 
conducted in accord with accepted standards of animal care. 
Surgery and treatment 
Surgery was carried out under isoflurane anesthesia, and with buprenorphine pain relief. 
Stainless steel infusion guide cannula (22G, Plastics One, Roanoke, VA, USA) was implanted 
into the right lateral cerebral ventricle (D=5.3 mm, L=1.4 mm, AP=0.8 mm). Alzet 2004 mini-
pumps filled with either 0.2 ml of pro-oxidant-containing 61.5 µM AβO solution or vehicle, 
were connected to the cannula via PE50 tubing (Plastics One) and placed under the skin in the 
interscapular region. Pumps released 1.67 µg AβO daily for 4 weeks. Dosage was selected 
based on the work of Frautschy et al. (Frautschy et al., 2001). After AβO infusion, minipumps 
were replaced with new ones filled with either 0.2 ml of 0.167 µg/ml MCC950 in artificial CSF 
(aCSF), or 0.2 ml of aCSF. Dose of MCC950 was calculated based on published data on IC50 
for NLRP3 (Coll et al., 2015). Pumps released 1.0 µg MCC950 daily for 4 weeks. Consecutive 
treatments generated four experimental groups including control group (vehicle + aCSF, n=6), 
drug control group (vehicle + DRUG, n=3), AβO challenged group (AβO + aCSF, n=6) and 
MCC950 treatment group (AβO + DRUG, n=8) were examined.  
Morris water-maze task 
On the fourth week of the second treatment, we started to perform Morris water maze (MWM). 
We tested spatial acquisition for 4 days, reversal on the next day and spatial learning for 2 days. 
The maze used in this study was a black circular pool (180 cm in diameter) filled to a 40 cm-
depth with 24oC water. The black platform (10 cm in diameter) was hidden 2 cm below the 
water surface in the SW quadrant. On each day, rats were given four successive trials with a 
maximum duration of 90 sec, the inter-trial interval was 1 minute. Starting points (N, E, NW, 
SE) were randomized (Vorhees & Williams, 2006). Multiple color distal cues were placed on 
the wall and remained there throughout the experiment. Performance was recorded and 
analyzed by the EthoVision software (Noldus, Wageningen, Netherlands). 
Isolation of total RNA from the hippocampus 
At the completion of the experiment, animals were deeply anaesthetized with a mixture of 
ketamine and xylazine (50 mg/kg ketamine, 10 mg/kg xylazine). After collection of CSF from 
the cisterna magna, animals for gene expression analysis were transcardially perfused with ice-
cold PBS containing 10% RNAlater (Invitrogen, Carlsbad, CA, USA). Brains were quickly 
removed from the skull and placed into an ice-cold RBM-4000C rat brain matrix (ASI 
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Instruments, Warren, MI, USA). A 4 mm thick coronal slice was dissected with two blades 
positioned at bregma -2.2 and -6.2. Hippocampal formations were dissected from this slice. 
Samples were collected in Eppendorf tubes containing 1  ml of ice-cold RNAlater, incubated 
on ice for 1 hour, frozen on dry ice and stored at -80oC. Total RNA was isolated using the 
RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany). RNA analytics included capillary 
electrophoresis using Nano RNA Chips on 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). 
cDNA synthesis was performed using the High Capacity cDNA Reverse Transcription Kit 
according to manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA). 
Real-time PCR 
TaqMan inventoried gene expression assays (Applied Biosystems) were used to study 
transcriptional regulation of 75 selected genes by real-time PCR. Glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh), hypoxanthine phosphoribosyl-transferase (Hprt1) and peptidyl-prolyl 
isomerase A (Ppia) were used as house-keeping genes. Each assay consisted of a FAM dye-
labeled TaqMan MGB probe and two PCR primers. Real-time PCR was performed on a ViiA7 
Real-Time PCR System (Applied Biosystems) as described earlier (Sarvari, Kallo, Hrabovszky, 
Solymosi, & Liposits, 2014). The ViiA7 RUO software and relative quantification against 
calibrator samples (ΔΔCt) were used for data analysis. A computed internal control 
corresponding to the geometric mean of Ct values of selected house-keeping genes was used 
for ΔCt calculation. Relative quantity (RQ = 2-ΔΔCt) was used to characterize gene expression 
in the various experimental groups. PCR experiments conformed to minimum information for 
publication of quantitative real-time PCR experiments (MIQE) guidelines (Bustin et al., 2009). 
Immunohistochemistry 
After behavioural tests, animals were deeply anaesthetized with a mixture of ketamine and 
xylazine, and CSF was collected from the cisterna magna. Three rats per group were perfused 
transcardially with PBS followed by 120 ml of 4% paraformaldehyde (PFA) in 0.1 M PBS.  
Brains were quickly removed from the skull and post-fixed overnight in 4% PFA. Brains were 
cryoprotected overnight in 30% sucrose and frozen on powdered dry ice. Coronal, 30 µm thick 
sections were prepared using a freezing microtome (SMR2000R, Leica Biosystems, Nussloch, 
Germany). Sections were collected into a series of six wells, thus each well contained 
consecutive sections that were 180 μm apart rostro-caudally from one another. 
For Iba1 immunohistochemistry (IHC), after pretreatment with a solution containing 0.5% 
Triton X-100 and 0.5% H2O2 in PBS for 20 minutes, sections were immersed in a rabbit 
polyclonal antiserum against Iba1 (1:2,000 dilution, #019-19741, Wako Chemicals) for 72 
hours at 4ºC, followed by 1-hour incubations in biotin conjugated anti-rabbit IgG (1:500 
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dilution, Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and ABC elite reagent 
(1:1,000 dilution, Vector Laboratories, Burlingame, CA, USA). The immunoreaction product 
was visualized with nickel-enhanced diaminobenzidine (0.15% NiNH4SO4, 0.005% H2O2, 
0.05% diaminobenzidine in Tris pH7.6). Sections were mounted on glass slides and 
coverslipped with DPX mounting medium (VWR, Radnor, PA, USA). Slides were analyzed 
using a Zeiss Axioskop-2 (Carl-Zeiss Microscopy, Jena, Germany) microscope. Sections were 
photographed with an AxioCam HRc digital camera controlled by AxioVision 4.6 software 
(Carl-Zeiss). Digital pictures were taken using 20x and 40x objectives. 
For immunofluorescent detection of Aβ1-42, sections were pretreated with a solution containing 
1% human serum albumin, 0.1% Triton X-100 and 1mg/ml digitonin for 1 hour and incubated 
with mouse monoclonal antibody against Aβ1-42 (#126649, Abcam) at the dilution of 1:200 for 
72 hours at 4oC. Cy3-conjugated anti-mouse IgG (1:500 dilution, Jackson ImmunoResearch 
Laboratories) was diluted in PBS containing 2% normal horse serum and applied on the sections 
for 2 hours. Similarly prepared sections from the cerebral cortex of APPNL-F/NL-F mice (Nilsson, 
Saito, & Saido, 2014) were used as positive controls. Sections were mounted on glass slides 
and coverslipped with VectaShield mounting medium (Vector Laboratories). Slides were 
investigated using a Zeiss Axioskop-2 microscope under epifluorescent illumination using a 
filter set for Cy3 dye. Specificity of the Aβ1-42 antibody was confirmed by the lack of staining 
on wild-type mouse tissue, and the characteristic staining in APPNL-F/NL-F mice with Aβ plaques. 
Cytometric bead array 
The measurement of rat IFNγ, IL-1α, IL-10 and TNFα was performed by cytometric bead array 
(CBA) as earlier (Denes et al., 2015), using BDTM CBA Flex Sets (BD Biosciences, Franklin 
Lakes, NJ, USA) according to manufacturer’s protocol. Samples were acquired on a BD 
FACSVerseTM flow cytometer and data analyzed using FCAP Array v3 software (BD 
Bioscience). 
Statistics 
In PCR data evaluation, group data were expressed as relative quantity: RQ(mean)±standard 
deviation. Statistical significance of the changes in gene expression was analyzed using one-
way ANOVA followed by Newman-Keuls post-hoc test (Statistica 13.1, Dell Software, Round 
Rock, TX, USA). In the assessment of MWM data, we used one-way ANOVA with Newman-
Keuls post-hoc test to determine probability of the changes. Differences were considered 
significant at p<0.05. 
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Results 
AβO infusion evoked lasting microglial activation and inflammation in the hippocampus 
We characterized changes of the microglia phenotype in the hippocampus after intracerebro-
ventricular (icv.) infusion AβO and artificial CSF by measuring the expression of Iba1, Cd11b, 
Cd68, Cd80, Cd86 and RT1-EC2 (Fig. 1A-F). All selected microglia reactivity markers were 
upregulated in the AβO challenged group compared to controls. IHC and quantitative 
evaluation of Iba1 immunoreactivity were performed to verify the presence of activated 
microglia (Fig. 1G). In accordance with elevated expression of reactivity marker genes, Iba1 
integrated density was significantly higher in the CA1 region of animals challenged with AβO 
compared to controls. To characterize further the microglia phenotype, we investigated mRNA 
expression of a set of microglia related genes encoding receptors for recognition, recruitment 
and phagocytosis (Table 1). Expression of all selected recognition (Tlr2, Tlr3, Tlr4, Tlr9, co-
receptor Cd14), recruitment (C3ar1, C5ar1, Ccr2, Cxcr4), phagocytic and scavenger receptor 
genes (Cd11b, Cd11c, Cd163, Cd18, Cd68, Crry, Fcgr1a, Fcgr2a, Fcgr2b, Fcgr3a, Mfge8, 
Mrc1) was enhanced in the AβO challenged group compared to controls.  
MCC950 treatment after AβO infusion reversed mRNA expression of all selected reactivity 
marker genes (Fig. 1A-F). MCC950 also decreased Iba1 integrated density (Fig. 1G) 
supporting the results of gene expression analysis described above. MCC950 fully reversed 
upregulation of recognition, recruitment and phagocytosis receptor genes (Table 1). 
We studied expression of selected chemokine, complement and cytokine genes, some of them 
related to the status of the transcription factor NF-κB (Table 2). Infusion of AβO and CSF 
robustly enhanced chemokine (Ccl2, Cxcl10) and complement (C3, Cfb) expression in the 
hippocampus. AβO also increased Nlrp3 and Il1b expression indicating activation of NF-κB.  
Upregulation of additional proinflammatory cytokines (Tnf, Il12b) and Nos2 supported the 
notion that microglia remained activated after icv. infusion of AβO and CSF. On the other hand, 
icv. infusion of MCC950 immediately after AβO infusion reduced expression of all pro-
inflammatory genes to control levels (Table 2) indicating that the NLRP3 inhibitor abolished 
NF-κB-dependent transcriptional activation.  
We couldn’t detect extracellular Aβ1-42 plaques in the hippocampus after AβO and CSF infusion 
(Fig. 2), although we detected Aβ1-42 immunoreactivity in the cerebral cortex of APPNL-F/NL-F 
mice (Nilsson et al., 2014). This finding indicated that microglia may have contributed to the 
elimination of AβO or prevented its accumulation in the brain, but remained activated after 
AβO challenge.  
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AβO infusion activated transcription of genes related to neuronal control of microglia 
Neurons control microglia reactivity by neuronal inhibitory ligands via their cognate microglial 
receptors (Hanisch & Kettenmann, 2007; Tian, Rauvala, & Gahmberg, 2009). After AβO and 
CSF infusion, expression of Cx3cl1 (Fig. 3A), Cd200 (Fig. 3B), and Cd22 (Fig. 3C) increased 
moderately, while their cognate microglial receptors, Cx3cr1 (Fig. 3D), Cd200r1 (Fig. 3E), and 
Cd45 (Fig. 3E) enhanced robustly compared to controls. Expression of other neuronal 
inhibitory ligands such as Cd47 (RQ=1.67±0.33, p=0.01) and Sema3a (RQ=1.63±0.15, 
p=0.001) elevated moderately. Transcription of Cd86, which is a key player in the modulation 
of the microglia phenotype (Louveau et al., 2015), also enhanced significantly (Fig. 1E). 
MCC950 treatment restored expression of both neuronal ligands and their microglial receptors 
(Fig. 3). 
AβO infusion altered expression of estrogen receptor genes  
Estradiol is synthesized from testosterone by aromatase in the hippocampus. Its effects are 
mediated by estrogen receptors, mainly via estrogen receptor alpha (ERα) and beta (ERβ), 
which are encoded by Esr1 and Esr2, respectively. AβO challenge inversely regulated the 
expression of estrogen receptors, decreased Esr1 (Fig. 4A) and increased Esr2 (Fig. 4B) 
expression. Inhibition of NLRP3 inflammasome activation restored Esr1 mRNA expression 
and attenuated upregulation of Esr2. 
AβO infusion suppressed Scn1a mRNA expression   
Interneuron-specific and parvalbumin-positive basket cell predominant voltage-gated sodium 
channel subunit Nav1.1 shows decreased expression in AD (Verret et al., 2012). As the process 
takes place at early phase of the disease, we followed mRNA expression Scn1a encoding the 
Na(v)1.1 subunit in the hippocampus after icv. infusion AβO and CSF. Scn1a expression was 
decreased (RQ=0.79±0.02, p=0.032), but MCC950 restored Scn1a (RQ=0.95±0.06) expression, 
although the change did not reach statistical significance (p=0.09).  
AβO infusion leads to impaired spatial memory 
Hippocampus-dependent spatial memory was tested in MWM tasks. During spatial acquisition, 
decreasing escape latency times indicated fast spatial learning in the case of the control groups 
from day 2 (Fig. 5A). Vehicle and drug control groups showed indistinguishable parameters, 
therefore only latency times of the vehicle control group were shown. The AβO challenged 
group showed higher latency times than controls from day 2, and the difference became 
statistically significant on day 4 (Fig. 5A).  
On day 5, the hidden platform was moved to the opposite quadrant (reversal) and spatial 
acquisition was followed for three days (Fig. 5B). Control animals learned the new position of 
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the platform fast, while the AβO challenged group showed impaired learning. The difference 
between latency times reached statistical significance on day 3 (Fig. 5B).  
In the MCC950 treatment group, we measured decreased latency times compared to the AβO 
challenged group, similar to control groups (Fig. 5A). After reversal, the MCC950 treatment 
group learned the new position of the platform fast, while the AβO challenged group showed 
impaired learning (Fig. 5B). The performance of control groups and the MCC950 treatment 
group was similar (and was not different statistically) indicating that MCC950 completely 
reversed AβO-evoked memory impairments. 
Blockade of the NLRP3 inflammasome reversed AβO-induced decreases in serum IL-10 
Activation of microglia and the NLRP3 inflammasome may influence immune-related cells in 
the circulation. Therefore, we investigated serum cytokine profiles by measuring concentrations 
of IL-1α, TNFα, IL-10 and IFNγ. TNFα and IFNγ levels were below the detection limit of the 
CBA assay. In contrast to the low serum levels of proinflammatory cytokines, concentrations 
of IL-10 (Fig. 6A) were 105±1.7pg/ml in control animals, which decreased to 83±14.0pg/ml in 
AβO challenged animals, but the change did not reach statistical significance (p=0.064). 
MCC950 treatment normalized serum IL-10. Serum levels of IL-1α (Fig. 6B) showed no 
difference among treatment groups. 
 
  
13 
 
Discussion 
The microglia driven innate immune response against AβO in the hippocampus is implicated 
in the pathogenesis of late-onset AD (Akiyama et al., 2000; Heneka et al., 2015; Lucin & Wyss-
Coray, 2009). To explore the AβO-induced microglia response and putative downstream 
mechanisms acting in the aging hippocampus, we induced an early AD-like neurological 
phenotype in middle-aged male rats by AβO (and CSF) infusion into the lateral cerebral 
ventricle. Then, we studied spatial memory, as well as selected molecular elements of the innate 
immune response and interneuron-related processes. To clarify the impact of the microglia 
driven innate immune response to AβO on spatial memory impairment in our middle-aged 
infusion model, we blocked activation of the NLRP3 inflammasome by icv. infusion of 
MCC950. 
Infusion of Aβ1-40 and Aβ1-42 into the cerebral ventricles of middle-aged rats is an established 
approach to mimic the neurological phenotype of late-onset AD (Frautschy et al., 2001; 
Frautschy et al., 1996). As familial AD mutations lead to increased Aβ1-42: Aβ1-40 ratio (Hardy, 
1997), and Aβ1-40 and Aβ1-42 are the predominant species in neuritic plaques of AD patients 
(Masters et al., 1985; Mori, Takio, Ogawara, & Selkoe, 1992), we chose Aβ1-42 to form 
oligomers. Of note, structure and composition of AβO are markedly different from the 
neurotoxic oligomers of Aβ1-40 (Ahmed et al., 2010). This structural difference goes with 
distinct prefibrillar to fibrillar oligomer transitions, and while AβO are stable at low temperature 
and low ionic strength, Aβ1-40 oligomers slowly form protofibrils and fibrils under the same 
condition (Ahmed et al., 2010; Glabe, 2008). Our oligomer preparation under low temperature-
low salt condition results in mainly pentamers (and decamers), but we cannot exclude the 
possibility that the structure and composition of AβO may change during infusion, although we 
found no sign of fibril formation. Using expression analysis and evaluation of Iba1 
immunoreactivity, we provided evidence that 4 weeks after AβO infusion still there is microglia 
activation in the hippocampus (Fig. 1). Although extracellular Aβ1-42 plaques were not present 
(Fig. 2), we found evidence for upregulation of chemokines, complement and proinflammatory 
cytokines indicating the activation of NF-κB (Table 2). Robust transcriptional activation of 
genes encoding C3-Cd11b/Cd18 ligand-receptor pairs indicated increased microglial 
phagocytosis. In accordance, upregulated production and activation of complement have been 
demonstrated in the AD brain (Eikelenboom & Stam, 1982; Yasojima, Schwab, McGeer, & 
McGeer, 1999). Early activation of complement in AD has been proved recently (Hong et al., 
2016; Zanjani et al., 2005). Upregulation of complement genes in the hippocampus after icv. 
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infusion AβO (Table 2) lends further support for the role of complement in early AD. Although 
we observed enhanced expression of some microglia receptors and their neuronal inhibitory 
ligands (Fig. 3), regulatory mechanisms were unable to prevent microglia activation after the 
encounter with AβO. Uncontrolled microglia activation coincided with downregulation of Esr1 
(Fig. 4) and Scn1a expression, and impairment of spatial memory (Fig. 5).  
Estradiol is synthesized from testosterone by aromatase in the hippocampus (Hojo et al., 2004). 
Its effects are mediated by estrogen receptors, mainly via ERα and ERβ, both of them are 
expressed in the rat hippocampus (Shughrue & Merchenthaler, 2000). In microglia, the 
expression of ERα and ERβ is still controversial. While both have been observed in vitro, only 
ERα has been observed in vivo (Sierra, Gottfried-Blackmore, Milner, McEwen, & Bulloch, 
2008). We found downregulation of Esr1 indicating possible impairment of powerful 
microglia-dependent anti-inflammatory mechanisms (Vegeto et al., 2003). The regulatory role 
of ERα-mediated E2 action in neuroinflammation and NLRP3 inflammasome activation 
remains largely unexplored in AD. On the other hand, reduced ERα expression may also have 
an impact on neuromodulation (B. McEwen et al., 2001), as ERα is localized in dendrites, 
dendritic spines, and presynaptic terminals (B. S. McEwen, Akama, Spencer-Segal, Milner, & 
Waters, 2012). ERα mediates translational regulation of synaptogenesis via activating protein 
synthesis for dendritic function (Akama & McEwen, 2003). In addition, ERα, associated with 
clusters of vesicles in perisomatic inhibitory boutons, regulates vesicle trafficking at inhibitory 
synapses (Hart, Snyder, Smejkalova, & Woolley, 2007). These effects make E2 a powerful 
regulator of the hippocampus. Cessation of ovarian E2 synthesis renders the hippocampus 
vulnerable to AβO and may contribute to the increased risk of AD in postmenopausal women 
(Henderson & Buckwalter, 1994). Decreased mRNA expression of ERα isoforms (Ishunina, 
Fischer, & Swaab, 2007) and reduced number of both cytoplasmic and nuclear ERα positive 
neurons (Hu et al., 2003) have been reported in the AD hippocampus. We found downregulation 
of Esr1 indicating impairment of powerful anti-inflammatory mechanisms (Vegeto et al., 2003) 
and neuromodulation (B. McEwen et al., 2001). ERα is localized at both nuclear and 
extranuclear sites of the hippocampus and expressed in dendrites, dendritic spines, presynaptic 
terminals and glial processes  (B. S. McEwen, Akama, Spencer-Segal, Milner, & Waters, 2012). 
ERα mediates translational regulation of synaptogenesis via activating protein synthesis for 
dendritic function (Akama & McEwen, 2003). In addition, ERα, associated with clusters of 
vesicles in perisomatic inhibitory boutons, regulates vesicle trafficking at inhibitory synapses 
(Hart, Snyder, Smejkalova, & Woolley, 2007). Importantly, decreased mRNA expression of 
15 
 
ERα isoforms (Ishunina, Fischer, & Swaab, 2007) and reduced number of both cytoplasmic and 
nuclear ERα positive neurons (Hu et al., 2003) has been reported in the AD hippocampus.  
Scn1a, which encodes the voltage-dependent sodium channel alpha subunit Na(v)1.1 expressed 
predominantly in parvalbumin-positive basket cells, is downregulated in AD brains at both 
mRNA and protein levels (Verret et al., 2012). The relationship between reduced Na(v)1.1 
expression, hypersynchrony and memory impairment has been established in AD (Verret et al., 
2012). AβO-induced downregulation of Esr1 and Scn1a may interfere with the function of 
inhibitory interneurons, which represent a link between NLRP3 inflammasome activation and 
memory decline. AβO-mediated memory decline became significant on the 4th day of spatial 
acquisition in MWM (Fig. 5), in accord with other studies using the middle-aged rat infusion 
model (Frautschy et al., 2001). 
We found that inhibition of the NLRP3 inflammasome by icv. infusion of MCC950 after AβO 
challenge attenuated AβO-evoked microglia reactivity (Fig. 1) and NF-κB activation, and 
abolished spatial memory impairment (Fig. 5). These observations agree with the results of 
recent pharmacological studies in APP transgenic mouse models (Daniels et al., 2016; Dempsey 
et al., 2016). An important novel observation that adds to these earlier studies is that AβO is 
sufficient to induce long-lasting inflammation and memory deficits in an NLRP3-dependent 
manner, even in the absence of major amyloid deposits in the brain parenchyma. In addition, 
we found that MCC950 restored transcriptomic changes of genes involved in neuron-microglia 
communication, and reversed downregulation of Esr1 and Scn1a, although in the latter case the 
effect did not reach statistical significance. As MCC950 infusion leads to the resolution of 
inflammation and restoration of spatial memory, it is likely that AβO-evoked inflammatory 
responses play causative role in the suppression of estrogen signaling, alteration of basket cell 
specific sodium transport and impairment of spatial memory. Based on these findings, we 
propose that AβO activates microglia, which persists even after the elimination of the 
pathogenic substance. Enduring activation of microglia interferes with ERα signaling and 
subunit composition of voltage-gated sodium channels in basket cells among others, resulting 
in reversible impairment of spatial learning and memory. 
Central inflammatory reactions may have an impact on the peripheral immune system, and vice 
versa. Cognitively impaired patients with amyloidosis have shown higher serum levels of 
proinflammatory cytokines and lower levels of IL-10 compared to patients without brain 
amyloidosis (Cattaneo et al., 2017). Therefore, activation of microglia in the hippocampus may 
influence immune-related cells in the circulation and alter the serum cytokine profiles. 
Although statistical significance was not achieved in our study, serum levels of IL-10 tended to 
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decrease in middle-aged rats following AβO challenge (Fig. 6). We demonstrated that serum 
levels of IL-10 were decreased in middle-aged rats following AβO challenge (Fig. 6). 
Importantly, serum IL-10 levels are affected in individuals with AD (Asselineau et al., 2015; 
Remarque et al., 2001; Swardfager et al., 2010). In peripheral blood mononuclear cells, IL-10 
synthesis is almost ceased in fast cognitive decliners, whereas its level is slightly increased in 
slow cognitive decliners with AD (Asselineau et al., 2015). In our middle-aged rat infusion 
model, MCC950 restored normal serum IL-10 levels (Fig. 6).  This finding gives support to the 
idea that AβO-induced microglia activation results in a decrease in serum IL-10 levels. 
Emerging evidence indicates that IL-10 acts in a negative feedback loop to regulate the NLRP3 
inflammasome during chronic stimulations (Gurung et al., 2015; Ip, Hoshi, Shouval, Snapper, 
& Medzhitov, 2017; Yao et al., 2015). A very recent paper has demonstrated that IL-10 
promotes mitophagy that eliminates dysfunctional mitochondria in macrophages (Ip et al., 
2017). However, the functional contribution of IL-10 to the transcriptomic, inflammatory and 
behavioral changes observed has not been tested in this study. This finding gives support to the 
idea that AβO-induced microglia activation results in a decrease in serum IL-10 levels. 
Proinflammatory cytokine TNFα were undetectable in the serum, while IL-1α levels showed 
no difference among the experimental groups. 
In conclusion, these results demonstrate that icv. infusion of AβO evokes lasting microglial and 
inflammatory responses in the hippocampus of middle-aged rats leading to reversible 
impairment of spatial memory.  The underlying mechanisms might include interference with 
Esr1 and Scn1a expression in the hippocampus, and peripheral IL-10-mediated action could 
potentially contribute to the changes observed, which will need to be tested in further studies.  
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Tables 
Table 1   Expression of recognition, recruitment and phagocytosis receptors associated with 
microglia in the rat hippocampus after AβO, artificial CSF and MCC950 infusions. 
 
  AβO+aCSF   AβO+MCC950 
Gene RQ SD p   RQ SD p 
   Recognition 
Cd14 5.32 1.99 0.005   1.77 0.35 0.399 
Tlr2 2.48 0.80 0.004   0.77 0.23 0.651 
Tlr3 3.20 1.09 0.003   0.88 0.18 0.741 
Tlr4 1.80 0.33 0.002   0.84 0.22 0.548 
Tlr9 1.76 0.38 0.020   0.87 0.05 0.586 
                
   Recruitment 
C3ar1 1.77 0.39 0.005   0.76 0.21 0.321 
C5ar1 3.00 1.48 0.027   1.02 0.32 0.965 
Ccr2 5.09 1.55 0.002   0.56 0.28 0.625 
Cxcr4 1.73 0.28 0.003   0.84 0.17 0.288 
                
   Phagocytosis 
Cd11b 4.12 1.29 0.000   0.79 0.21 0.494 
Cd11c 14.37 6.80 0.033   1.99 0.75 0.850 
Cd163 1.63 0.22 0.012   0.97 0.03 0.893 
Cd18 2.80 0.49 0.001   0.83 0.14 0.579 
Cd68 3.52 1.17 0.005   0.89 0.33 0.867 
Crry 1.31 0.09 0.006   0.83 0.13 0.043 
Fcgr1a 3.81 0.83 0.001   1.01 0.28 0.993 
Fcgr2a 1.89 0.26 0.001   1.17 0.18 0.222 
Fcgr2b 4.14 1.31 0.006   1.17 0.28 0.827 
Fcgr3a 5.85 1.60 0.001   0.90 0.19 0.900 
Mfge8 1.24 0.06 0.043   0.99 0.14 0.716 
Mrc1 2.09 0.18 0.001   0.90 0.22 0.519 
                
 
Twenty-one genes, encoding microglia receptors involved in recognition, recruitment and 
phagocytosis, were selected and studied by quantitative real-time PCR. AβO- and MCC950-
evoked changes were compared to controls. One-way ANOVA with Newman-Keuls post-hoc 
test was used for statistical analysis. In the case of AβO+MCC950, p values greater than 0.05 
show that mRNA expression of genes in drug treated animals did not differ from controls. RQ, 
relative quantity; SD, standard deviation; p, probability. 
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Table 2   Expression of selected chemokine, complement and cytokine genes in the 
hippocampus after AβO, artificial CSF and MCC950 infusions. 
 
  AβO+aCSF   AβO+MCC950 
Gene RQ SD p   RQ SD p 
   Chemokines 
Ccl2 10.88 1.91 0.000   1.58 0.32 0.667 
Cxcl10 4.22 0.69 0.001   0.92 0.26 0.806 
Cxcl12 1.09 0.20     1.05 0.16   
                
   Complement 
C3 7.62 4.37 0.011   0.86 0.54 0.979 
Cfb 10.84 3.08 0.001   0.93 0.22 0.996 
Cfd 2.13 0.09 0.000   0.96 0.04 0.609 
Cfh 1.87 0.24 0.000   0.98 0.15 0.960 
Cfp 1.58 0.11 0.000   1.02 0.13 0.944 
Clu 1.22 0.09 0.104   0.78 0.18 0.110 
Serping1 3.70 0.90 0.000   0.84 0.17 0.715 
                
   Cytokines 
Il1b 1.99 0.58 0.004   0.84 0.42 0.584 
Il10 1.32 0.18     0.63 0.19   
Il12b 4.32 0.65 0.008   1.21 0.86 0.887 
Il6 1.22 0.19     0.91 0.04   
Tgfb1 2.04 0.10 0.000   0.96 0.25 0.648 
Tnf 3.62 0.28 0.000   0.96 0.18 0.696 
                
   Other 
Nlrp3 1.87 0.12 0.000   0.83 0.10 0.143 
Nos2 12.00 1.24 0.000   0.57 0.57 0.532 
                
 
Eighteen genes encoding chemokines, complement and cytokines were selected and studied by 
quantitative real-time PCR. AβO- and MCC950-induced changes were compared to controls. 
One-way ANOVA with Newman-Keuls post-hoc test was used for statistical analysis. RQ, 
relative quantity; SD, standard deviation; p, probability. 
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Legends to figures 
Figure 1  Infusion of AβO and CSF enhanced microglia reactivity in the hippocampus. 
AβO (A+CSF, n=6) increased mRNA expression of microglial reactivity marker genes (A) 
Aif1/Iba1, (B) Cd11b/Itgam, (C) Cd68, (D) Cd80, (E) Cd86 and (F) RT1-EC2 compared to 
controls (CTRL). MCC950 treatment (A+DRUG, n=8) attenuated AβO-induced upregulation 
of all marker genes. Quantitative real-time PCR with inventoried gene expression assays were 
applied to determine mRNA levels in AβO plus aCSF (A+CSF), AβO plus MCC950 
(A+DRUG) and control groups (CTRL). One-way ANOVA with Newman-Keuls post-hoc test 
was used to determine statistical significance (asterisks). (G) Iba1 IHC in the CA1 region of 
the rat hippocampus. Using Iba1 immunostaining we demonstrated AβO-evoked changes of the 
microglia phenotype. The alteration manifested primarily in the enhanced Iba1 integrated 
density in microglia.  
Figure 2 Aβ1-42 immunohistochemistry. Detection of Aβ1-42 immunoreactivity in the 
cerebral cortex of (A) middle-aged control rats, (B) AβO challenged middle-aged rats, (C) 11 
months old wild-type mice and (D) APPNL-F/NL-F mice. Arrows mark strong Aβ1-42 immuno-
reactivity indicating the presence of extracellular Aβ plaques. Scale bar is 50 µm. 
Figure 3 AβO infusion enhanced mRNA expression of genes involved in neuronal control 
of microglia reactivity. AβO challenge (A+CSF, n=6, black column) activated transcription of 
(A) Cx3cl1, (B) Cd200, (C) Cd22, (D) Cx3cr1, (E) Cd200r and (F) Cd45 compared to controls 
(CTRL, white column). MCC950 treatment (A+DRUG, n=8, striped column) abated 
transcriptional activation of all genes encoding neuronal inhibitory ligands and their cognate 
microglial receptors. Gene expression was determined by quantitative real-time PCR. One-way 
ANOVA with Newman-Keuls post-hoc test was used to evaluate statistical significance. 
Figure 4 AβO challenge altered the expression of estrogen receptor genes. (A) AβO 
(A+CSF, black column) decreased mRNA expression of Esr1 compared to controls (CTRL, 
white column). MCC950 (A+DRUG, striped column) restored Esr1 expression. (B) AβO 
increased mRNA expression of Esr2 compared to controls. Inhibition of NLRP3 inflammasome 
attenuated upregulation of Esr2. 
Figure 5 Morris water maze tasks, (A) spatial acquisition and (B) reversal, revealed 
impairments of spatial memory. AβO challenged (A+CSF, black solid line, n=6), controls 
(CTRL, grey, n=6) and AβO plus MCC950 (A+DRUG, black dashed line, n=8) groups were 
examined, and displayed mean of the latencies in relation to the trial number. On each day, rats 
were given four consecutive trials of a maximum duration of 90 sec. Control (CTRL) and drug 
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control (VEH+DRUG) groups performed identically, therefore only data of the control group 
were shown. One-way ANOVA with Newman-Keuls post-hoc test was used for statistical 
analysis.  
Figure 6 Infusion of AβO had an impact on serum cytokine profile. (A) AβO challenge 
(A+CSF, n=6, black column) decreased serum IL-10 levels compared to controls (CTRL, n=6, 
white column), although the change did not reach statistical significance (p=0.064). MCC950 
after AβO infusion (A+DRUG, n=8, striped column) reversed declining serum levels of IL-10. 
(B) There was no change in IL-1α levels among treatment groups. Serum IL-10 levels were 
determined by cytometric bead technology. One-way ANOVA with Newman-Keuls post-hoc 
test was used to analyze statistical significance. 
 
  
  
22 
 
References 
Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., . . . Smith, S. O. (2010). Structural 
conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol, 17(5), 
561-567. doi:10.1038/nsmb.1799 
Akama, K. T., & McEwen, B. S. (2003). Estrogen stimulates postsynaptic density-95 rapid protein 
synthesis via the Akt/protein kinase B pathway. J Neurosci, 23(6), 2333-2339.  
Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., . . . Wyss-Coray, T. (2000). 
Inflammation and Alzheimer's disease. Neurobiol Aging, 21(3), 383-421.  
Asselineau, D., Benlhassan, K., Arosio, B., Mari, D., Ferri, E., Casati, M., . . . Bray, D. H. (2015). 
Interleukin-10 Production in Response to Amyloid-beta Differs between Slow and Fast 
Decliners in Patients with Alzheimer's Disease. J Alzheimers Dis, 46(4), 837-842. 
doi:10.3233/JAD-142832 
Bilousova, T., Miller, C. A., Poon, W. W., Vinters, H. V., Corrada, M., Kawas, C., . . . Gylys, K. H. (2016). 
Synaptic Amyloid-beta Oligomers Precede p-Tau and Differentiate High Pathology Control 
Cases. Am J Pathol, 186(1), 185-198. doi:10.1016/j.ajpath.2015.09.018 
Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., . . . Glabe, C. (1992). 
Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide 
analogs. J Biol Chem, 267(1), 546-554.  
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., . . . Wittwer, C. T. (2009). 
The MIQE guidelines: minimum information for publication of quantitative real-time PCR 
experiments. Clin Chem, 55(4), 611-622. doi:10.1373/clinchem.2008.112797 
Cattaneo, A., Cattane, N., Galluzzi, S., Provasi, S., Lopizzo, N., Festari, C., . . . Group, I.-F. (2017). 
Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral 
inflammation markers in cognitively impaired elderly. Neurobiol Aging, 49, 60-68. 
doi:10.1016/j.neurobiolaging.2016.08.019 
Coll, R. C., Robertson, A. A., Chae, J. J., Higgins, S. C., Munoz-Planillo, R., Inserra, M. C., . . . O'Neill, L. A. 
(2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of 
inflammatory diseases. Nat Med, 21(3), 248-255. doi:10.1038/nm.3806 
Daniels, M. J., Rivers-Auty, J., Schilling, T., Spencer, N. G., Watremez, W., Fasolino, V., . . . Brough, D. 
(2016). Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's 
disease in rodent models. Nat Commun, 7, 12504. doi:10.1038/ncomms12504 
Dempsey, C., Rubio Araiz, A., Bryson, K. J., Finucane, O., Larkin, C., Mills, E. L., . . . Lynch, M. A. (2016). 
Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of 
amyloid-beta and cognitive function in APP/PS1 mice. Brain Behav Immun. 
doi:10.1016/j.bbi.2016.12.014 
Denes, A., Coutts, G., Lenart, N., Cruickshank, S. M., Pelegrin, P., Skinner, J., . . . Brough, D. (2015). AIM2 
and NLRC4 inflammasomes contribute with ASC to acute brain injury independently of NLRP3. 
Proc Natl Acad Sci U S A, 112(13), 4050-4055. doi:10.1073/pnas.1419090112 
Eikelenboom, P., & Stam, F. C. (1982). Immunoglobulins and complement factors in senile plaques. An 
immunoperoxidase study. Acta Neuropathol, 57(2-3), 239-242.  
El Khoury, J., Hickman, S. E., Thomas, C. A., Cao, L., Silverstein, S. C., & Loike, J. D. (1996). Scavenger 
receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature, 382(6593), 716-719. 
doi:10.1038/382716a0 
Forny-Germano, L., Lyra e Silva, N. M., Batista, A. F., Brito-Moreira, J., Gralle, M., Boehnke, S. E., . . . De 
Felice, F. G. (2014). Alzheimer's disease-like pathology induced by amyloid-beta oligomers in 
nonhuman primates. J Neurosci, 34(41), 13629-13643. doi:10.1523/JNEUROSCI.1353-14.2014 
Frautschy, S. A., Hu, W., Kim, P., Miller, S. A., Chu, T., Harris-White, M. E., & Cole, G. M. (2001). Phenolic 
anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and 
neuropathology. Neurobiol Aging, 22(6), 993-1005.  
23 
 
Frautschy, S. A., Yang, F., Calderon, L., & Cole, G. M. (1996). Rodent models of Alzheimer's disease: rat 
A beta infusion approaches to amyloid deposits. Neurobiol Aging, 17(2), 311-321.  
Garcia-Matas, S., de Vera, N., Aznar, A. O., Marimon, J. M., Adell, A., Planas, A. M., . . . Sanfeliu, C. 
(2010). In vitro and in vivo activation of astrocytes by amyloid-beta is potentiated by pro-
oxidant agents. J Alzheimers Dis, 20(1), 229-245. doi:10.3233/JAD-2010-1365 
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V., Perrot, L. J., . . . Araoz, C. (1989). Brain 
interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer 
disease. Proc Natl Acad Sci U S A, 86(19), 7611-7615.  
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., . . . Golenbock, D. T. 
(2008). The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. 
Nat Immunol, 9(8), 857-865. doi:10.1038/ni.1636 
Halverson, K., Fraser, P. E., Kirschner, D. A., & Lansbury, P. T., Jr. (1990). Molecular determinants of 
amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein 
fragments. Biochemistry, 29(11), 2639-2644.  
Hanisch, U. K., & Kettenmann, H. (2007). Microglia: active sensor and versatile effector cells in the 
normal and pathologic brain. Nat Neurosci, 10(11), 1387-1394. doi:10.1038/nn1997 
Hart, S. A., Snyder, M. A., Smejkalova, T., & Woolley, C. S. (2007). Estrogen mobilizes a subset of 
estrogen receptor-alpha-immunoreactive vesicles in inhibitory presynaptic boutons in 
hippocampal CA1. J Neurosci, 27(8), 2102-2111. doi:10.1523/JNEUROSCI.5436-06.2007 
He, Y., Zheng, M. M., Ma, Y., Han, X. J., Ma, X. Q., Qu, C. Q., & Du, Y. F. (2012). Soluble oligomers and 
fibrillar species of amyloid beta-peptide differentially affect cognitive functions and 
hippocampal inflammatory response. Biochem Biophys Res Commun, 429(3-4), 125-130. 
doi:10.1016/j.bbrc.2012.10.129 
Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Brosseron, F., Feinstein, D. L., . . . Kummer, 
M. P. (2015). Neuroinflammation in Alzheimer's disease. Lancet Neurol, 14(4), 388-405. 
doi:10.1016/S1474-4422(15)70016-5 
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., . . . Golenbock, 
D. T. (2013). NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 
mice. Nature, 493(7434), 674-678. doi:10.1038/nature11729 
Hojo, Y., Hattori, T. A., Enami, T., Furukawa, A., Suzuki, K., Ishii, H. T., . . . Kawato, S. (2004). Adult male 
rat hippocampus synthesizes estradiol from pregnenolone by cytochromes P45017alpha and 
P450 aromatase localized in neurons. Proc Natl Acad Sci U S A, 101(3), 865-870. 
doi:10.1073/pnas.2630225100 
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., . . . Stevens, B. (2016). 
Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science, 
352(6286), 712-716. doi:10.1126/science.aad8373 
Hu, X. Y., Qin, S., Lu, Y. P., Ravid, R., Swaab, D. F., & Zhou, J. N. (2003). Decreased estrogen receptor-
alpha expression in hippocampal neurons in relation to hyperphosphorylated tau in Alzheimer 
patients. Acta Neuropathol, 106(3), 213-220. doi:10.1007/s00401-003-0720-3 
Ishunina, T. A., Fischer, D. F., & Swaab, D. F. (2007). Estrogen receptor alpha and its splice variants in 
the hippocampus in aging and Alzheimer's disease. Neurobiol Aging, 28(11), 1670-1681. 
doi:10.1016/j.neurobiolaging.2006.07.024 
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989). Relationship of microglia and 
astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol, 24(3), 173-182.  
Kadish, I., Thibault, O., Blalock, E. M., Chen, K. C., Gant, J. C., Porter, N. M., & Landfield, P. W. (2009). 
Hippocampal and cognitive aging across the lifespan: a bioenergetic shift precedes and 
increased cholesterol trafficking parallels memory impairment. J Neurosci, 29(6), 1805-1816. 
doi:10.1523/JNEUROSCI.4599-08.2009 
Kirschner, D. A., Inouye, H., Duffy, L. K., Sinclair, A., Lind, M., & Selkoe, D. J. (1987). Synthetic peptide 
homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc 
Natl Acad Sci U S A, 84(19), 6953-6957.  
24 
 
Kuo, Y. M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., . . . Roher, 
A. E. (1996). Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease 
brains. J Biol Chem, 271(8), 4077-4081.  
Lecanu, L., Greeson, J., & Papadopoulos, V. (2006). Beta-amyloid and oxidative stress jointly induce 
neuronal death, amyloid deposits, gliosis, and memory impairment in the rat brain. 
Pharmacology, 76(1), 19-33. doi:10.1159/000088929 
Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., . . . Ashe, K. H. (2006). A specific 
amyloid-beta protein assembly in the brain impairs memory. Nature, 440(7082), 352-357. 
doi:10.1038/nature04533 
Li, X., Long, J., He, T., Belshaw, R., & Scott, J. (2015). Integrated genomic approaches identify major 
pathways and upstream regulators in late onset Alzheimer's disease. Sci Rep, 5, 12393. 
doi:10.1038/srep12393 
Louveau, A., Nerriere-Daguin, V., Vanhove, B., Naveilhan, P., Neunlist, M., Nicot, A., & Boudin, H. 
(2015). Targeting the CD80/CD86 costimulatory pathway with CTLA4-Ig directs microglia 
toward a repair phenotype and promotes axonal outgrowth. Glia, 63(12), 2298-2312. 
doi:10.1002/glia.22894 
Lucin, K. M., & Wyss-Coray, T. (2009). Immune activation in brain aging and neurodegeneration: too 
much or too little? Neuron, 64(1), 110-122. doi:10.1016/j.neuron.2009.08.039 
Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., . . . Rogers, J. (1999). Soluble amyloid 
beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J 
Pathol, 155(3), 853-862.  
Maezawa, I., Zimin, P. I., Wulff, H., & Jin, L. W. (2011). Amyloid-beta protein oligomer at low nanomolar 
concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem, 286(5), 
3693-3706. doi:10.1074/jbc.M110.135244 
McEwen, B., Akama, K., Alves, S., Brake, W. G., Bulloch, K., Lee, S., . . . Milner, T. A. (2001). Tracking the 
estrogen receptor in neurons: implications for estrogen-induced synapse formation. Proc Natl 
Acad Sci U S A, 98(13), 7093-7100. doi:10.1073/pnas.121146898 
McEwen, B. S., Akama, K. T., Spencer-Segal, J. L., Milner, T. A., & Waters, E. M. (2012). Estrogen effects 
on the brain: actions beyond the hypothalamus via novel mechanisms. Behav Neurosci, 126(1), 
4-16. doi:10.1037/a0026708 
McGeer, P. L., Itagaki, S., Tago, H., & McGeer, E. G. (1987). Reactive microglia in patients with senile 
dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. 
Neurosci Lett, 79(1-2), 195-200.  
Muller-Schiffmann, A., Herring, A., Abdel-Hafiz, L., Chepkova, A. N., Schable, S., Wedel, D., . . . Korth, 
C. (2016). Amyloid-beta dimers in the absence of plaque pathology impair learning and 
synaptic plasticity. Brain, 139(Pt 2), 509-525. doi:10.1093/brain/awv355 
Muruve, D. A., Petrilli, V., Zaiss, A. K., White, L. R., Clark, S. A., Ross, P. J., . . . Tschopp, J. (2008). The 
inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune 
response. Nature, 452(7183), 103-107. doi:10.1038/nature06664 
Nilsson, P., Saito, T., & Saido, T. C. (2014). New mouse model of Alzheimer's. ACS Chem Neurosci, 5(7), 
499-502. doi:10.1021/cn500105p 
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005). Resting microglial cells are highly dynamic 
surveillants of brain parenchyma in vivo. Science, 308(5726), 1314-1318. 
doi:10.1126/science.1110647 
Rathinam, V. A., & Fitzgerald, K. A. (2016). Inflammasome Complexes: Emerging Mechanisms and 
Effector Functions. Cell, 165(4), 792-800. doi:10.1016/j.cell.2016.03.046 
Reed-Geaghan, E. G., Savage, J. C., Hise, A. G., & Landreth, G. E. (2009). CD14 and toll-like receptors 2 
and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci, 29(38), 
11982-11992. doi:10.1523/JNEUROSCI.3158-09.2009 
Remarque, E. J., Bollen, E. L., Weverling-Rijnsburger, A. W., Laterveer, J. C., Blauw, G. J., & Westendorp, 
R. G. (2001). Patients with Alzheimer's disease display a pro-inflammatory phenotype. Exp 
Gerontol, 36(1), 171-176.  
25 
 
Ryan, T. M., Caine, J., Mertens, H. D., Kirby, N., Nigro, J., Breheney, K., . . . Roberts, B. R. (2013). 
Ammonium hydroxide treatment of Abeta produces an aggregate free solution suitable for 
biophysical and cell culture characterization. PeerJ, 1, e73. doi:10.7717/peerj.73 
Sarvari, M., Kallo, I., Hrabovszky, E., Solymosi, N., & Liposits, Z. (2014). Ovariectomy and subsequent 
treatment with estrogen receptor agonists tune the innate immune system of the 
hippocampus in middle-aged female rats. PLoS One, 9(2), e88540. 
doi:10.1371/journal.pone.0088540 
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., . . . Selkoe, D. J. 
(2008). Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic 
plasticity and memory. Nat Med, 14(8), 837-842. doi:10.1038/nm1782 
Shughrue, P. J., & Merchenthaler, I. (2000). Evidence for novel estrogen binding sites in the rat 
hippocampus. Neuroscience, 99(4), 605-612.  
Swardfager, W., Lanctot, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010). A meta-
analysis of cytokines in Alzheimer's disease. Biol Psychiatry, 68(10), 930-941. 
doi:10.1016/j.biopsych.2010.06.012 
Tian, L., Rauvala, H., & Gahmberg, C. G. (2009). Neuronal regulation of immune responses in the central 
nervous system. Trends Immunol, 30(2), 91-99. doi:10.1016/j.it.2008.11.002 
Vegeto, E., Belcredito, S., Etteri, S., Ghisletti, S., Brusadelli, A., Meda, C., . . . Maggi, A. (2003). Estrogen 
receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc Natl Acad Sci U 
S A, 100(16), 9614-9619. doi:10.1073/pnas.1531957100 
Verret, L., Mann, E. O., Hang, G. B., Barth, A. M., Cobos, I., Ho, K., . . . Palop, J. J. (2012). Inhibitory 
interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer 
model. Cell, 149(3), 708-721. doi:10.1016/j.cell.2012.02.046 
Vorhees, C. V., & Williams, M. T. (2006). Morris water maze: procedures for assessing spatial and 
related forms of learning and memory. Nat Protoc, 1(2), 848-858. doi:10.1038/nprot.2006.116 
Wang, Z., Jackson, R. J., Hong, W., Taylor, W. M., Corbett, G. T., Moreno, A., . . . Walsh, D. M. (2017). 
Human Brain-Derived Abeta Oligomers Bind to Synapses and Disrupt Synaptic Activity in a 
Manner That Requires APP. J Neurosci, 37(49), 11947-11966. doi:10.1523/JNEUROSCI.2009-
17.2017 
Yasojima, K., Schwab, C., McGeer, E. G., & McGeer, P. L. (1999). Up-regulated production and activation 
of the complement system in Alzheimer's disease brain. Am J Pathol, 154(3), 927-936. 
doi:10.1016/S0002-9440(10)65340-0 
Zanjani, H., Finch, C. E., Kemper, C., Atkinson, J., McKeel, D., Morris, J. C., & Price, J. L. (2005). 
Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc Disord, 19(2), 55-
66.  
 
 
 
